Emergent BioSolutions (EBS) Enterprise Value (2010 - 2026)

Emergent BioSolutions' Enterprise Value history runs 17 years deep, the most recent figure standing at -$161.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 5.69% year-over-year to -$161.5 million in Q1 2026; TTM through Mar 2026 was -$161.5 million, a 5.69% decrease from a year earlier, with the FY2025 full-year figure at -$209.1 million, down 98.01% from the prior year.
• Enterprise Value improved to -$161.5 million in Q1 2026 per EBS's latest filing, from -$209.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$71.0 million in Q2 2024 and bottomed at -$642.6 million in Q4 2022.
• The 5-year median for Enterprise Value is -$161.5 million (2026), against an average of -$226.6 million.
• Across the five-year window, Enterprise Value jumped 82.62% in 2023 and slumped 281.69% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$642.6 million in 2022, then soared by 82.62% to -$111.7 million in 2023, then increased by 5.46% to -$105.6 million in 2024, then slumped by 98.01% to -$209.1 million in 2025, then increased by 22.76% to -$161.5 million in 2026.
• Per Business Quant, the three latest EBS Enterprise Value figures stand at -$161.5 million (Q1 2026), -$209.1 million (Q4 2025), and -$249.2 million (Q3 2025).